Annabel Samimy
Stock Analyst at Stifel Nicolaus
(4.82)
# 477
Out of 4,988 analysts
399
Total ratings
50.5%
Success rate
18.2%
Average return
Main Sectors:
Stocks Rated by Annabel Samimy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IVA Inventiva | Reiterated: Buy | $15 | $3.78 | +296.83% | 19 | Sep 18, 2026 | |
| LGND Ligand Pharmaceuticals | Reiterated: Buy | $332 | $283.49 | +17.11% | 9 | Aug 14, 2026 | |
| OCS Oculis Holding AG | Reiterated: Buy | $40 | $10.14 | +294.48% | 12 | Aug 14, 2026 | |
| TSX: EPRX Eupraxia Pharmaceuticals Inc. | Reiterated: Buy | $34.99 | $11.97 | +192.35% | 4 | Aug 12, 2026 | |
| MBX MBX Biosciences | Reiterated: Buy | $56 → $70 | $62.91 | +11.27% | 11 | Aug 11, 2026 | |
| GPCR Structure Therapeutics | Reiterated: Buy | $90 | $35.00 | +157.14% | 9 | Aug 7, 2026 | |
| TRVI Trevi Therapeutics | Reiterated: Buy | $30 | $14.95 | +100.67% | 25 | Aug 7, 2026 | |
| EOLS Evolus | Reiterated: Buy | $17 | $7.86 | +116.28% | 27 | Aug 6, 2026 | |
| JAZZ Jazz Pharmaceuticals | Reiterated: Buy | $230 → $275 | $240.74 | +14.23% | 42 | Aug 4, 2026 | |
| VKTX Viking Therapeutics | Reiterated: Buy | $95 | $28.99 | +227.70% | 25 | Jul 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $40 | $3.85 | +938.96% | 1 | Jul 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $42 | $8.03 | +423.04% | 26 | Jun 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $250 | $150.56 | +66.05% | 9 | Jun 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $52 | $28.02 | +85.58% | 13 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $55 | $42.00 | +30.95% | 31 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $28 | $7.48 | +274.33% | 6 | Jan 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $3.25 | - | 7 | Dec 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $0.862 | n/a | 9 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $2,633.00 | n/a | 3 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.63 | n/a | 19 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $11 | $7.08 | n/a | 13 | Aug 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $21.00 → $19.60 | $7.92 | n/a | 24 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $63 | $0.0074 | n/a | 6 | Oct 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $5 → $15 | $1.89 | n/a | 4 | Jun 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $6 → $5 | $2.19 | n/a | 20 | May 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $80 → $87 | $13.56 | n/a | 14 | Aug 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $7 | $8.07 | n/a | 8 | Nov 7, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $110.29 | n/a | 1 | Jan 13, 2014 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $27 | $16.03 | n/a | 1 | Dec 4, 2013 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $56 | $33.64 | n/a | 1 | Oct 18, 2011 |
Inventiva
Sep 18, 2026
Reiterated: Buy
Price Target: $15
Current: $3.78
Upside: +296.83%
Ligand Pharmaceuticals
Aug 14, 2026
Reiterated: Buy
Price Target: $332
Current: $283.49
Upside: +17.11%
Oculis Holding AG
Aug 14, 2026
Reiterated: Buy
Price Target: $40
Current: $10.14
Upside: +294.48%
Eupraxia Pharmaceuticals Inc.
Aug 12, 2026
Reiterated: Buy
Price Target: $34.99
Current: $11.97
Upside: +192.35%
MBX Biosciences
Aug 11, 2026
Reiterated: Buy
Price Target: $56 → $70
Current: $62.91
Upside: +11.27%
Structure Therapeutics
Aug 7, 2026
Reiterated: Buy
Price Target: $90
Current: $35.00
Upside: +157.14%
Trevi Therapeutics
Aug 7, 2026
Reiterated: Buy
Price Target: $30
Current: $14.95
Upside: +100.67%
Evolus
Aug 6, 2026
Reiterated: Buy
Price Target: $17
Current: $7.86
Upside: +116.28%
Jazz Pharmaceuticals
Aug 4, 2026
Reiterated: Buy
Price Target: $230 → $275
Current: $240.74
Upside: +14.23%
Viking Therapeutics
Jul 30, 2026
Reiterated: Buy
Price Target: $95
Current: $28.99
Upside: +227.70%
Jul 16, 2026
Initiated Coverage: Buy
Price Target: $40
Current: $3.85
Upside: +938.96%
Jun 25, 2026
Reiterated: Buy
Price Target: $42
Current: $8.03
Upside: +423.04%
Jun 24, 2026
Reiterated: Buy
Price Target: $250
Current: $150.56
Upside: +66.05%
May 7, 2026
Reiterated: Buy
Price Target: $52
Current: $28.02
Upside: +85.58%
May 6, 2026
Reiterated: Hold
Price Target: $55
Current: $42.00
Upside: +30.95%
Jan 15, 2026
Reiterated: Buy
Price Target: $28
Current: $7.48
Upside: +274.33%
Dec 19, 2025
Reiterated: Buy
Price Target: n/a
Current: $3.25
Upside: -
Apr 1, 2025
Reiterated: Buy
Price Target: $8
Current: $0.862
Upside: n/a
Jan 8, 2025
Reiterated: Buy
Price Target: n/a
Current: $2,633.00
Upside: n/a
Dec 19, 2024
Rated: Hold
Price Target: n/a
Current: $1.63
Upside: n/a
Aug 30, 2023
Reiterated: Hold
Price Target: $11
Current: $7.08
Upside: n/a
Nov 3, 2022
Reiterated: Buy
Price Target: $21.00 → $19.60
Current: $7.92
Upside: n/a
Oct 19, 2022
Downgraded: Hold
Price Target: $63
Current: $0.0074
Upside: n/a
Jun 30, 2022
Downgraded: Hold
Price Target: $5 → $15
Current: $1.89
Upside: n/a
May 6, 2021
Reiterated: Buy
Price Target: $6 → $5
Current: $2.19
Upside: n/a
Aug 9, 2018
Reiterated: Hold
Price Target: $80 → $87
Current: $13.56
Upside: n/a
Nov 7, 2016
Reiterated: Hold
Price Target: $7
Current: $8.07
Upside: n/a
Jan 13, 2014
Downgraded: Hold
Price Target: n/a
Current: $110.29
Upside: n/a
Dec 4, 2013
Initiated Coverage: Buy
Price Target: $27
Current: $16.03
Upside: n/a
Oct 18, 2011
Rated: Buy
Price Target: $56
Current: $33.64
Upside: n/a